Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a medical technology company focused on innovative solutions for Obstructive Sleep Apnea (OSA), has announced the release of its third quarter 2024 financial results on November 6, 2024, after market close. The company will host a conference call to discuss the results on the same day at 10:30pm CET / 4:30pm ET.
Investors can access the call via webcast through the Investor Relations page of Nyxoah's website or a provided link. Those planning to ask questions should register using a separate link, which will provide dial-in details and a unique conference call access code. Registration is recommended at least 10 minutes before the call starts. An archived webcast will be available for replay after the call concludes.
Nyxoah SA (Euronext Bruxelles/Nasdaq: NYXH), un'azienda di tecnologia medica focalizzata su soluzioni innovative per l'apnea ostruttiva del sonno (OSA), ha annunciato il rilascio dei risultati finanziari del terzo trimestre 2024 il 6 novembre 2024, dopo la chiusura del mercato. L'azienda ospiterà una conferenza telefonica per discutere i risultati lo stesso giorno alle 22:30 CET / 16:30 ET.
Gli investitori possono accedere alla chiamata tramite webcast attraverso la pagina delle Relazioni con gli Investitori del sito web di Nyxoah o tramite un link fornito. Coloro che intendono porre domande devono registrarsi utilizzando un link separato, che fornirà i dettagli per la chiamata e un codice d'accesso unico per la conferenza. È consigliata la registrazione almeno 10 minuti prima dell'inizio della chiamata. Un webcast archiviato sarà disponibile per la riproduzione dopo la conclusione della chiamata.
Nyxoah SA (Euronext Bruselas/Nasdaq: NYXH), una empresa de tecnología médica centrada en soluciones innovadoras para la apnea obstructiva del sueño (OSA), ha anunciado la publicación de sus resultados financieros del tercer trimestre de 2024 el 6 de noviembre de 2024, después del cierre del mercado. La empresa llevará a cabo una conferencia telefónica para discutir los resultados el mismo día a las 10:30pm CET / 4:30pm ET.
Los inversores pueden acceder a la llamada a través de un webcast en la página de Relaciones con Inversores del sitio web de Nyxoah o mediante un enlace proporcionado. Aquellos que planeen hacer preguntas deben registrarse utilizando un enlace separado, que proporcionará los detalles para la llamada y un código de acceso único para la conferencia. Se recomienda registrarse al menos 10 minutos antes de que comience la llamada. Un webcast archivado estará disponible para su reproducción después de que concluya la llamada.
Nyxoah SA (Euronext 브뤼셀/Nasdaq: NYXH), 폐쇄성 수면 무호흡증 (OSA)에 대한 혁신적인 솔루션에 초점을 맞춘 의료 기술 회사가 2024년 3분기 재무 결과를 2024년 11월 6일에 시장이 마감된 후 발표한다고 발표했습니다. 회사는 같은 날 CET 10:30pm / ET 4:30pm에 결과를 논의하기 위한 컨퍼런스 콜을 진행합니다.
투자자들은 Nyxoah 웹사이트의 투자자 관계 페이지를 통해 또는 제공된 링크를 통해 콜에 접속할 수 있습니다. 질의를 하실 예정인 분들은 별도의 링크를 이용해 등록해야 하며, 해당 링크는 전화 접속 세부 정보와 고유한 컨퍼런스 콜 접근 코드를 제공합니다. 통화 시작 10분 전에 등록하는 것이 권장됩니다. 콜 종료 후 다시 듣기 위해 아카이브된 웹캐스트가 제공될 예정입니다.
Nyxoah SA (Euronext Bruxelles/Nasdaq: NYXH), une entreprise de technologie médicale axée sur des solutions innovantes pour l'apnée obstructive du sommeil (OSA), a annoncé la publication de ses résultats financiers du troisième trimestre 2024 le 6 novembre 2024, après la clôture des marchés. L'entreprise organisera une conférence téléphonique le même jour à 22h30 CET / 16h30 ET pour discuter des résultats.
Les investisseurs peuvent accéder à l'appel via un webcast sur la page des Relations Investisseurs du site web de Nyxoah ou via un lien fourni. Ceux qui prévoient de poser des questions doivent s'inscrire via un lien séparé, qui fournira les détails d'appel et un code d'accès unique à la conférence. Il est recommandé de s'inscrire au moins 10 minutes avant le début de l'appel. Un webcast archivé sera disponible pour lecture après la fin de l'appel.
Nyxoah SA (Euronext Brüssel/Nasdaq: NYXH), ein Medizintechnikunternehmen, das sich auf innovative Lösungen für obstruktive Schlafapnoe (OSA) konzentriert, hat die Veröffentlichung seiner Finanzergebnisse für das dritte Quartal 2024 für den 6. November 2024 nach Börsenschluss angekündigt. Das Unternehmen wird am selben Tag um 22:30 Uhr CET / 16:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu erörtern.
Investoren können die Konferenz über einen Webcast auf der Investor-Relations-Seite der Nyxoah-Website oder über einen bereitgestellten Link zugreifen. Personen, die Fragen stellen möchten, sollten sich über einen separaten Link registrieren, der die Einwahl-Details und einen einzigartigen Zugangscode für die Telefonkonferenz bereitstellt. Eine Registrierung wird empfohlen, mindestens 10 Minuten vor Beginn der Konferenz. Ein archivierter Webcast wird nach Abschluss der Konferenz zur Verfügung stehen.
- None.
- None.
Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024
Mont-Saint-Guibert, Belgium – October 22, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the third quarter 2024 on Wednesday, November 6, 2024, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET.
A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's Q3 2024 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.
If you plan to ask a question, please use the following link: Nyxoah’s Q3 2024 earnings call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.
The archived webcast will be available for replay shortly after the close of the call.
About Nyxoah
Nyxoah is reinventing sleep for the billion people that suffer from obstructive sleep apnea (OSA). We are a medical technology company that develops breakthrough treatment alternatives for OSA through neuromodulation. Our first innovation is Genio®, a battery-free hypoglossal neuromodulation device that is inserted through a single incision under the chin and controlled by a wearable. Through our commitment to innovation and clinical evidence, we have shown best-in-class outcomes for reducing OSA burden.
Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study for FDA and U.S. commercialization approval.
Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.
FORWARD-LOOKING STATEMENTS
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and reporting data from Nyxoah’s DREAM U.S. pivotal trial; receipt of FDA approval; entrance to the U.S. market; and the anticipated closing and use of the proceeds from the offering. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2024, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in the offering, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
Contacts:
Nyxoah
Loïc Moreau, Chief Financial Officer
IR@nyxoah.com
For Media
In United States
FINN Partners – Glenn Silver
glenn.silver@finnpartners.com
In Belgium/France
Backstage Communication – Gunther De Backer
gunther@backstagecom.be
In International/Germany
MC Services – Anne Hennecke
nyxoah@mc-services.eu
Attachment
FAQ
When will Nyxoah (NYXH) release its Q3 2024 financial results?
What time is Nyxoah's (NYXH) Q3 2024 earnings call scheduled for?
How can investors access Nyxoah's (NYXH) Q3 2024 earnings call?
What is Nyxoah's (NYXH) main focus as a medical technology company?
